A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Description

The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI, and to see whether the use of the fluorescent imaging agent pHLIP ICG and NIRF imaging during surgery is a safe approach that may allow the surgeon to see the tumor and nearby tissues that contain cancer cells more clearly and remove them completely. During the Phase IIa part of this study, the safe dose of pHLIP ICG will be used that makes it easy for the surgeon to see the tumor and the nearby tissues and structures that may contain cancer cells. This study is the first to test pHLIP ICG in people, and the first to test the use of pHLIP ICG with mpMRI and NIRF imaging in surgery for breast cancer.

Conditions

Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI, and to see whether the use of the fluorescent imaging agent pHLIP ICG and NIRF imaging during surgery is a safe approach that may allow the surgeon to see the tumor and nearby tissues that contain cancer cells more clearly and remove them completely. During the Phase IIa part of this study, the safe dose of pHLIP ICG will be used that makes it easy for the surgeon to see the tumor and the nearby tissues and structures that may contain cancer cells. This study is the first to test pHLIP ICG in people, and the first to test the use of pHLIP ICG with mpMRI and NIRF imaging in surgery for breast cancer.

Phase I/IIa Study of Pre-operative Multiparametric MRI and pHLIP® ICG Intra-operative Fluorescence Imaging of Primary Breast Cancer

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Montvale

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States, 07645

New York

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or greater
  • * Biopsy proven primary breast malignancy (BI-RADS 6)
  • * Tumor stage Tis, T1 and T2, lesion size \> 1 cm
  • * Primary surgical treatment with breast conservation
  • * No previous treatment
  • * No contraindications for MRI or MRI contrast agents or high-field MRI (3T)
  • * ECOG performance of 0-2
  • * Life expectancy \< 3 months
  • * Pregnancy or lactation
  • * Known contrast agent allergies that require premedication before MRI.
  • * Patients who cannot undergo multiparametric MRI scanning because of:
  • * Weight limits. MRI scanners may not be able to function with patients over 450 pounds.
  • * Severe claustrophobia/ examination associated anxiety.
  • * MRI unsafe implant
  • * Known metastatic liver disease, hepatic neoplasms (benign and malignant), biliary atresia, chronic liver disease (CLD) and cirrhosis.
  • * Known moderate hepatic impairment (in phase I, and in phase IIa dependent on safety profile established in phase I)
  • * Known hypersensitivity to indocyanine green.
  • * Individuals with impaired-decision making capacity

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Memorial Sloan Kettering Cancer Center,

Clarissa Lin, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

2026-11